B2065 Stem Cell Injection for Adults With Acute Ischemic Stroke
Tests B2065, a stem cell injection, against placebo in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: A Study of B2065 in Patients With Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07371624, who can take part
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tasly Pharmaceutical Group Co., Ltd
- Trial code
- NCT07371624
- Record updated
- 13 August 2026
- Original description
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are:Read full original descriptionShow less
A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Adipose-Derived Mesenchymal Stromal Cell Injection (B2065) in Participants With Acute Ischemic Stroke.
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are:
At what dose range is the drug safe for participants?
Which dose shows preliminary efficacy?
Researchers will compare B2065 to a placebo (a look-alike substance that contains no drug) to see if B2065 works to treat acute ischemic stroke.
Participants will:
Receive a single dose of B2065 during hospitalization
Visit the hospital as scheduled for safety and efficacy assessments
Inclusion: Aged 18 to 75 years (inclusive of the boundary values), with no restriction on sex; Patients with ischemic stroke confirmed by imaging examinations (CT/MRI); Time from onset of stroke symptoms to administration of the investigational product ≤36 hours; for wake-up stroke, the time of onset is defined as the last-known-well time (the last time the patient was observed to be normal); NIHSS score at screening is 8 to 20; The patient or legally authorized representative is willing to participate in this trial and agrees to sign the informed consent form.
Exclusion: Patients who have received intravenous thrombolysis and/or mechanical thrombectomy prior to dosing; Body temperature >38°C prior to dosing, and the investigator assesses that there is a risk of infection; Patients with uncontrollable active infection; or patients who have received systemic anti-infective therapy within 7 days prior to dosing and, in the investigator's judgment, may be likely to convert to uncontrollable active infection in the short term; Patients with other acquired or congenital immunodeficiency diseases, or those currently using immunosuppressants; Patients who participated in any other clinical trial within 1 month prior to screening; Patients who are allergic to any component of the investigational product; Modified Rankin Scale (mRS) score ≥2 before stroke onset; Patients who currently have intracranial hemorrhagic diseases (e.g., intracerebral hemorrhage, epidural hematoma, subarachnoid hemorrhage, etc.), or who have brain tumors, cerebrovascular malformations, multiple sclerosis, a history of severe traumatic brain injury, encephalitis, or other conditions causing stroke-like symptoms; Patients who may have major neurologic or psychiatric disorders that seriously interfere with the participant's compliance with trial assessments; Patients with malignant tumors or other diseases with an expected survival of less than 2 years; Patients who, upon screening inquiry, have alcohol dependence or a history of drug abuse; Patients with current or prior severe diseases of other organ systems, including but not limited to:; Patients with severe heart failure (NYHA Class III or IV) and/or severe respiratory failure; Patients with renal disease with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²; Advanced liver disease, such as hepatitis or liver cirrhosis; Patients positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg); patients positive for hepatitis B e antibody (HBeAb) and/or hepatitis B core antibody (HBcAb) with quantitative HBV-DNA above the upper limit of normal; patients with any of the following test results positive: hepatitis C virus antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab), or human immunodeficiency virus antibody (HIV-Ab); Patients with hypertension not controlled after taking therapeutic medications, with systolic blood pressure ≥185 mmHg and/or diastolic blood pressure ≥110 mmHg; Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL); Screening laboratory tests meeting any of the following criteria:; Serum alanine aminotransferase (ALT) ≥3× upper limit of normal (ULN); Serum aspartate aminotransferase (AST) ≥3× ULN; Serum creatinine (Cr) ≥2× ULN; Absolute neutrophil count (ANC) <1.5×10\^9/L; Platelet count (PLT) <100×10\^9/L; Hemoglobin (Hgb) <90 g/L; International normalized ratio (INR) >1.7 or activated partial thromboplastin time (APTT) >1.25× ULN; Patients who are unable to undergo CT and/or MRI examinations; Patients with decreased level of consciousness (NIHSS item 1a score ≥2); Pregnant or breastfeeding women; or those who plan to conceive, donate sperm, or donate oocytes during the trial and/or are unwilling to take effective contraception measures; Patients deemed by the investigator to be unsuitable for participation in this trial.